Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Blood Cancer Journal
|
June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Meletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
The Lancet. Haematology
|
December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Kwee Yong, William Wilson, Ruth M de Tute, et al.
British Journal of Haematology
|
March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study
Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
Blood Advances
|
February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
Sheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Blood Advances
|
December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Frits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Frontiers in Oncology
|
September 9, 2020
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London
Beth Russell, Charlotte Moss, Sophie Papa, et al.
Cell Reports. Medicine
|
December 30, 2020
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder
Sheila K Pierson, Johnson S Khor, Jasira Ziglar, et al.
Blood
|
September 6, 2018
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee, Peter Voorhees, Angela Dispenzieri, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Blood Cancer Journal
|
June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Meletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
The Lancet. Haematology
|
December 18, 2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Kwee Yong, William Wilson, Ruth M de Tute, et al.
British Journal of Haematology
|
March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study
Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.
Blood Advances
|
February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
Sheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Blood Advances
|
December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Frits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Frontiers in Oncology
|
September 9, 2020
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London
Beth Russell, Charlotte Moss, Sophie Papa, et al.
Cell Reports. Medicine
|
December 30, 2020
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder
Sheila K Pierson, Johnson S Khor, Jasira Ziglar, et al.
Blood
|
September 6, 2018
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee, Peter Voorhees, Angela Dispenzieri, et al.
Page
of 3